NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX). Investors who purchased ImmunityBio securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/ibrx.
The investigation concerns whether ImmunityBio has violated federal securities laws.
On May 11, 2023, Reuters reported that the U.S. Food and Drug Administration declined to approve ImmunityBio’s combination therapy to treat a type of bladder cancer due to deficiencies in its application. The Company also reiterated doubts about its ability to remain in business in a filing with the Securities and Exchange Commission. Following this news, ImmunityBio stock dropped nearly 57% to $2.69 per share during premarket trading hours that same day.
If you are aware of any facts relating to this investigation or purchased ImmunityBio shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/ibrx. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.